Gel-Coat Biomaterials

Name

Gel-Coat Biomaterials

Legal name

株式会社Gel Coat Biomaterials

Website

https://gelcoatbio.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Biomaterial Technology

NAICS

Resin and Synthetic Rubber Manufacturing (32521), Paint and Coating Manufacturing (325510), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Plastic Materials, Synth Resins & Nonvulcan Elastomers (2821), Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro industry

PRIMARYIMAEABAK

Specialty Polymers & Resins (Engineered Materials)

Industrials, Manufacturing & Construction/Chemicals & Industrial Materials/Specialty Chemicals

SECONDARYIMAEAOAH

Biodegradable Coatings & Barrier Layers (paper/packaging barriers)

Industrials, Manufacturing & Construction/Chemicals & Industrial Materials/Biodegradable Materials

SECONDARYIMAEAOAL

Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates)

Industrials, Manufacturing & Construction/Chemicals & Industrial Materials/Biodegradable Materials

Keywords

• Biomolecule stabilization
• Hydrogel biomaterial licensing
• Enzyme stabilization technology
• Anti-fouling membrane coatings
• Zwitterionic polymer materials

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Exclusive Technology Licensing: The company provides exclusive licensing of its proprietary Gel Coat™ biomaterial technology. This is the primary revenue model, targeting pharmaceutical companies, chemical manufacturers, and biotech firms for use in drug development, bio-manufacturing, and medical devices.
2. Custom Hydrogel Development Services: Joint development with customers to customize hydrogel formulations for specific applications. Customer-specific applications include enzyme stabilization, coating solutions, and filtration membrane modifications. Multiple major enterprise joint research projects are already in progress.
3. Extension Round Additional Funding: The company announced plans for a 100 million yen extension round following the Series A, indicating ongoing capital raising as part of its business development model.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

Gel-Coat Biomaterials develops and exclusively licenses its proprietary zwitterionic amoeba-type hydrogel platform, branded Gel Coat™, which encapsulates and stabilizes biomolecules (enzymes, proteins, nucleic acids, cells) while preserving their activity under extreme conditions. The company delivers the technology to enterprise customers in pharmaceutical, biotech, chemical, medical device, semiconductor, and marine sectors through exclusive licensing agreements and custom co-development of hydrogel formulations tailored to specific customer applications.

Product overview

Gel-Coat Biomaterials offers a single unified product platform built around its proprietary Gel Coat™ zwitterionic hydrogel technology. This amoeba-like hydrogel encapsulates and stabilizes biological materials (enzymes, antibodies, proteins, nucleic acids, cells, tissues) by retaining free water within nano-scale polymer structures. The technology is delivered primarily through exclusive licensing to pharmaceutical, chemical, food, and environmental companies. Applications span enzyme stabilization for industrial bio-processes, protein protection for bio-pharmaceuticals, biofouling prevention coatings, silicone surface hydrophilization, and in-body power generation devices. The company also develops custom hydrogel formulations tailored to specific customer applications through collaborative development partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

• Gel Coat™ Exclusive Licensing Program Exclusive licensing program for the proprietary Gel Coat™ zwitterionic amoeba hydrogel platform, granting enterprise customers rights to use the biomolecule stabilization and surface coating technology in pharmaceutical, biotech, chemical, medical device, semiconductor, and marine applications.
• Custom Hydrogel Development Services

Quantifiable outcome

• Enzyme storage temperature reduced from -30°C to 4°C with 4 weeks stability
• +6 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Six partnerships are on record, tiered core, core research partner, technology partner, flagship research partner and core technology origin.

• Waseda University (早稲田大学)coreStrategic or Co-development PartnerDaisuke Niwa, Board Chairman, is from Waseda University Venture Partners. Company leverages Waseda University's research network and startup support ecosystem. Waseda University Ventures manages the Series A investment vehicle.
• Daisen Membrane Systems Co., Ltd. (ダイセン・メンブレン・システムズ株式会社)core research partnerStrategic or Co-development PartnerJoint research collaboration with Gel Coat Biomaterials and the University of Tokyo to develop anti-fouling membrane coating technology. Research published in MRS Communications journal. Daisen contributed membrane expertise to the coating technology development targeting the filtration and separation market.
• Microbial Chemistry Research Foundation, Institute of Microbial Chemistry (公益財団法人 微生物化学研究会 微生物化学研究所)core research partnerStrategic or Co-development PartnerJoint research with GCB and the University of Tokyo to develop microbial attachment prevention coating technology. Published in Nikkan Kogyo Shimbun (May 2026). The research team developed a hydrogel-based coating that effectively prevents biofilm formation by bacteria and fungi on various surfaces.
• Samco Corporation (サムコ株式会社)technology partnerTechnology or IntegrationEquipment manufacturer partner providing plasma treatment equipment for silicone surface hydrophilization experiments. GCB used Samco's Aqua Plasma® Cleaner AQ-500 for plasma treatment of silicone surfaces prior to Gel Coat™ application. Collaboration achieved 31+ days of sustained superhydrophilicity on PDMS surfaces.
• Honda Motor Co., Ltd. (本田技研工業株式会社)flagship research partnerStrategic or Co-development PartnerJoint research team with Tokyo University and Honda developed next-generation biosensor technology featured in Nature.com. Professor Takai's zwitterionic polymer hydrogel expertise was applied to a minimally invasive microneedle biosensor for detecting driver fatigue and stress. Future applications include painless continuous glucose monitoring for diabetic patients.
• Tokyo University Graduate School of Engineering, Takai Laboratory (東京大学 大学院工学系研究科 高井まどか研究室)core technology originStrategic or Co-development PartnerThe company's foundational technology originates from Professor Madoka Takai's laboratory at the University of Tokyo. GCB was spun off from this academic research. The laboratory serves as an ongoing joint research partner and the CTO (Professor Takai) is the co-founder of the company. The partnership provides continuous innovation pipeline for new Gel Coat™ applications.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Codexis: Codexis engineers enzymes for pharmaceutical and industrial biocatalysis, sharing Gel Coat Biomaterials' focus on enzyme stabilization and performance enhancement. Both companies sell enabling technology to pharma and chemical manufacturers rather than competing as end-product producers, and both leverage deep polymer/protein science to create licensing-grade platforms.
• CellSeed: CellSeed is a Japan-based regenerative medicine company commercializing hydrogel-based cell sheet technology originating from Tokyo Women's Medical University. As a fellow Japan-based hydrogel platform company targeting medical applications, it is one of the closest direct comparables in geography, technology category, and commercialization stage.
• Carmell Therapeutics: Carmell Therapeutics develops plasma-derived bioactive materials for wound healing and orthopedic applications, sharing Gel Coat Biomaterials' model of licensing proprietary biomaterial platforms to medical device and pharmaceutical customers. Both companies focus on stabilizing biological activity within engineered material matrices.

Broad incumbents

• Novonesis (formerly Novozymes): Novonesis is the global leader in industrial enzymes and microbiome solutions, serving pharmaceutical, food, and bio-manufacturing customers at scale. While not a hydrogel company, it is the dominant incumbent whose enzyme customers would be natural licensees of Gel Coat™ stabilization technology, making it both a potential competitor in stabilization IP and a key channel partner.
• Smith+Nephew: Smith+Nephew is a global medical device major with an extensive wound care portfolio built largely on hydrogel and foam dressing technology. It represents the kind of established incumbent that could either license Gel Coat™ for next-generation wound care products or compete with in-house R&D against the platform.
• 3M Health Care: 3M's Health Care division produces a wide range of medical adhesives, coatings, and drug delivery components using proprietary polymer chemistry. As a broad incumbent with deep medical device channel relationships, it is a natural enterprise customer and potential competitive benchmark for Gel Coat Biomaterials' coating and drug delivery applications.
• Lubrizol Life Science Health: Lubrizol's Life Science Health division produces specialty polymers, excipients, and hydrogel technologies for pharmaceutical and medical device applications. It is one of the largest specialty polymer incumbents in the markets where Gel Coat Biomaterials is positioning its zwitterionic chemistry as a differentiated alternative.
• Hempel Foundation: Hempel is one of the world's largest marine coatings suppliers with a major anti-fouling product portfolio. Its existing ship hull coating customers represent a logical enterprise licensing channel for Gel Coat Biomaterials' anti-biofilm technology targeting the 35-50% biofouling-related fuel consumption penalty.
• AkzoNobel Marine Coatings: AkzoNobel Marine Coatings (International brand) is the global leader in marine and protective coatings with extensive anti-fouling technology. As an incumbent whose product roadmap is shaped by IMO carbon regulations, it is a direct comparison point for the marine anti-biofilm application and a potential licensee.

Emerging players

• Cyfuse Biomedical: Cyfuse Biomedical is a Japan-based bio-3D printing company developing cell-based regenerative medicine products using proprietary hydrogel and scaffold technologies. As a fellow Japanese emerging biomaterials company targeting medical applications, it represents a comparable peer in geography and stage, though with a different technical approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gel-coat-biomaterials-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gel-Coat Biomaterials